JUL 26   

Licence Agreement with Kobayashi for the Commercial Launch of Fortacin in Japan


JUL 25   

Estimated Results for the First Half of 2024


JUL 16   

Change of Auditor


JUL 14   

Next Day Disclosure Return


JUL 04   

Monthly Return of Equity Issuer on Movements in Securities


JUL 02   

Termination of Discloseable Transaction on Disposal of 25% Equity Interest in the Target Company


JUN 14   

Discloseable Transaction - Disposal of Listed Securities


JUN 03   

Monthly Return of Equity Issuer on Movements in Securities


MAY 31   

Supplemental Announcement to the 2023 Annual Report


MAY 30   

Poll Results of the Annual General Meeting Held on 30 May 2024


MAY 02   

Monthly Return of Equity Issuer on Movements in Securities


APR 25   

Notice of Annual General Meeting


APR 03   

Monthly Return of Equity Issuer on Movements in Securities


MAR 28   

Audited Final Results for the Year Ended 31 December 2023


MAR 25   

Discloseable Transaction - Disposal of 25% Equity Interest in the Target Company


MAR 15   

Date of Board Meeting


MAR 01   

Monthly Return of Equity Issuer on Movements in Securities


FEB 20   

Profit Warning


FEB 02   

Monthly Return of Equity Issuer on Movements in Securities


JAN 03   

Monthly Return of Equity Issuer on Movements in Securities